NSRX

Nasus Pharma Ltd.

8.10 USD
+0.05
0.62%
At close Aug 15, 4:00 PM EDT
After hours
8.08
-0.02
0.25%
1 day
0.62%
5 days
1.25%
1 month
-1.82%
3 months
-1.82%
6 months
-1.82%
Year to date
-1.82%
1 year
-1.82%
5 years
-1.82%
10 years
-1.82%
 

About: Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Funds holding %
of 7,366 funds
Analysts bullish %

Fund manager confidence

Research analyst outlook

We haven’t received any recent analyst ratings for NSRX.

Financial journalist opinion

Based on 3 articles about NSRX published over the past 30 days

Neutral
Seeking Alpha
14 hours ago
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some small issuers may still price. Street research is expected for seven companies in the week ahead, and three lock-up periods will be expiring.
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Neutral
GlobeNewsWire
1 day ago
Nasus Pharma Announces Closing of Initial Public Offering
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the closing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share. The gross proceeds of the offering were $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses. Nasus Pharma's shares began trading on the NYSE American LLC exchange on August 13, 2025 under the ticker symbol “NSRX”. Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, to purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions.
Nasus Pharma Announces Closing of Initial Public Offering
Neutral
GlobeNewsWire
3 days ago
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the pricing of its initial public offering of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10 million, prior to deducting underwriting discounts, commissions, and other offering expenses and excluding any exercise of the underwriters' option to purchase any additional securities as described herein. In addition, Nasus Pharma has granted the underwriters an option for a period of up to 45 days from the date of the final prospectus, purchase up to an additional 187,500 Ordinary Shares at the initial public offering price, less the underwriting discounts and commissions, to cover the over-allotment, if any.
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
Neutral
Seeking Alpha
1 month ago
Nasus Pharma IPO Shows Promise But Risks Remain
Nasus Pharma is developing a needle-free intranasal epinephrine spray for severe allergies, showing promising but early trial results in a small population. The company is thinly capitalized, faces a long regulatory path, and must compete with established players like EpiPen in a growing $4.4B market. Management seeks $11 million in IPO proceeds to fund further trials and scale-up but lacks major pharma partnerships or prominent VC backing.
Nasus Pharma IPO Shows Promise But Risks Remain
Charts implemented using Lightweight Charts™